Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Besifovir + L-carnitine vs TAF in CHB with NAFLD
NCT03604016Phase 4Unknown
- Sponsor
- Ildong Pharmaceutical Co Ltd
- Start
- Sep 2018
- Primary completion
- Jul 2020
- Modality
- Small Molecules
01
Overview
Phase 4, randomised, open-label trial of adefovir dipivoxil in Chronic Hepatitis B (CHB) (2 arms), sponsored by Ildong Pharmaceutical Co Ltd. Primary endpoint: Rate of subjects with HBV DNA undetected (< 20 IU/mL) at 48 weeks. Status: unknown.
02
Drugs
adefovir dipivoxil
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT03604016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03604016.